Trial Profile
A Phase IIb , Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-explorating Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Telitacicept (Primary) ; Azathioprine; Ciclosporin; Cyclophosphamide; Leflunomide; Methotrexate; Mycophenolate; Tacrolimus
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors RemeGen
- 12 Dec 2023 Results assessing efficacy and safety of telitacicept in active systemic lupus erythematosus, published in the Annals of the Rheumatic Diseases.
- 02 Mar 2020 Status changed from active, no longer recruiting to completed.
- 15 Nov 2019 According to an RemeGen media release, Dr. Wu is the lead investigator of the trial.